Claims for Patent: 8,816,047
✉ Email this page to a colleague
Summary for Patent: 8,816,047
Title: | Compositions and methods of using proislet peptides and analogs thereof |
Abstract: | Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof. |
Inventor(s): | Levetan; Claresa S. (Rosemont, PA), Garsky; Victor M. (Blue Bell, PA), Upham; Loraine V. (Albuquerque, NM) |
Assignee: | Cure DM Group Holdings, LLC (Wynnewood, PA) |
Application Number: | 12/674,573 |
Patent Claims: | 1. A peptide consisting of the sequence of SEQ ID NO: 7 (HIP2B).
2. A pharmaceutical composition comprising a peptide consisting of the sequence of SEQ ID NO: 7 (HIP2B). 3. The pharmaceutical composition of claim 2, wherein said peptide is present in a therapeutically effective amount. 4. The pharmaceutical composition of claim 3, wherein said therapeutically effective amount is selected from the group consisting of about 20 mg and about 30-60 mg. 5. The pharmaceutical composition of claim 3, wherein said therapeutically effective amount is equivalent to a dose selected from a group consisting of about 0.5 to about 5 mg/kg, about 0.5 to about 1.0 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1.0 mg/kg, about 5 mg/kg, and 8-20 mg/kilogram. 6. The pharmaceutical composition of claim 3, wherein the therapeutically effective amount is from about 400-800 mg per day, 60 to about 180 mg/day, or from about 60 to about 120 mg/day. 7. The pharmaceutical composition of claim 2 further comprising a pharmaceutically acceptable excipient. 8. A method of treating type 2 diabetes in a subject in need thereof comprising administering to the subject the peptide of claim 1. 9. A method of treating type 2 diabetes in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a peptide consisting of the sequence of SEQ ID NO: 7 (HIP2B). 10. The method of claim 8, wherein said peptide is administered in a therapeutically effective amount. 11. The method of claim 9, wherein said pharmaceutical composition comprises a therapeutically effective amount of the peptide. 12. The method of claim 8, further comprising administering a pancreatic islet cell regeneration agent, wherein said agent is selected from the group consisting of amylin, pramlintide, exendin-4, GIP, GLP-1, GLP-1 receptor agonists, GLP-1 analogs, hamster INGAP peptide, liraglutide, dipeptidyl peptidase inhibitor and combinations thereof. 13. The method of claim 9, further comprising administering an agent selected from the group consisting of: teplizumab, abatacept, rapamycin, FK506, IL-2, aldesleukin, lisofylline (1-[(5R)-5-Hydroxyhexyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione), interferon-alpha, diazoxide, a statin, mycophenolate mofetil, daclizumab, rituximab; campath-1H, polyclonal anti-T-lymphocyte globulin, pegfilgrastim, vitamin D, anakinra, deoxyspergualin and combinations thereof. 14. The method of claim 13, wherein the statin is atorvastatin. 15. The method of claim 11, wherein the therapeutically effective amount is about 20 mg. 16. The method of claim 11, wherein the therapeutically effective amount is about 30 to about 60 mg. 17. The method of claim 11, wherein the therapeutically effective amount is equivalent to a dose selected from a group consisting of about 0.5 to about 5 mg/kg, about 0.5 to about 1.0 mg/kg, and about 8-20 mg/kilogram. 18. The method of claim 11, wherein the therapeutically effective amount is equivalent to a dose selected from a group consisting of about 0.1 mg/kg, about 0.5 mg/kg, about 1.0 mg/kg, and about 5 mg/kg. 19. The method of claim 11, wherein the therapeutically effective amount is from about 400 to about 800 mg/day, 60 to about 180 mg/day, or from about 60 to about 120 mg/day. |
Details for Patent 8,816,047
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2027-08-30 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2027-08-30 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2027-08-30 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2027-08-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.